Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 2,476 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HSCT Clear all

Conditions: Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions: iodine I 131 monoclonal antibody BC8, busulfan, cyclophosphamide, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, cyclosporine, methotrexate, laboratory biomarker analysis; Radiation · Drug · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 16 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 3
States / cities: Richland, Washington • Seattle, Washington

Conditions: Leukemia, Lymphoma, Hematologic Malignancy
Interventions: Arm 1; Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hematologic Malignancy
Interventions: Exercise training; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Congenital Hemolytic Anemia, Sickle Cell Disease
Interventions: Peripheral blood hematopoietic progenitor cell (PBPC) transplant, Alemtuzumab, Peripheral blood hematopoietic progenitor cell Apheresis, Sirolimus; Procedure · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Lymphoblastic Leukemia (ALL)
Interventions: Moxetumomab Pasudotox; Biological
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 6 Months to 24 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 4
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 1 more

Conditions: Myeloma, Plasma-Cell, Lymphoma, Malignant, Myeloproliferative Disorders, Myelodysplastic Syndromes, Waldenstrom's Macroglobulinemia
Interventions: Reduced intensity conditioning with allogeneic transplant; Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Graft Versus Host Disease, Hematologic Neoplasms
Interventions: Busulfan, Fludarabine, Cyclophosphamide, Mycophenolate Mofetil, Sirolimus; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 120 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Azacitidine (AZC), Venetoclax; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Lung Injury, Acute, Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans
Interventions: Etanercept; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 6 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hypopituitarism, Hypogonadism, Thyroid Dysfunction, Bone Diseases, Metabolic
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 2 Years to 24 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ovarian Cancer
Interventions: mitoxantrone hydrochloride, thiotepa, topotecan hydrochloride, peripheral blood stem cell transplantation; Drug · Procedure
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: AML, ALL, CLL, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Aplastic Anemia, Myeloproliferative Disorder
Interventions: Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: Up to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Blood Cancer, Leukemia
Interventions: Cyclosporine, Anti-thymocyte globulin (ATG), Mycophenolate mofetil (MMF), Filgrastim, Total Lymphoid Irradiation (TLI); Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 50 Years to 70 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Multiple Myeloma
Interventions: Teclistamab, Lenalidomide; Drug
Lead sponsor: European Myeloma Network B.V.; Network
Eligibility: 18 Years and older
Enrollment: 1,594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 39
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 31 more

Conditions: Multiple Myeloma
Interventions: Propranolol; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hematologic Diseases, Stem Cell Transplants
Interventions: PUL-042; Drug
Lead sponsor: Pulmotect, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions: Laboratory Biomarker Analysis, Selinexor; Other · Drug
Lead sponsor: University of Chicago; Other
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ovarian Cancer
Interventions: filgrastim, carmustine, cisplatin, melphalan, paclitaxel, peripheral blood stem cell transplantation, surgical procedure; Biological · Drug · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML), Juvenile Myelomonocytic Leukemia(JMML), Hemoglobinuria, Paroxysmal Nocturnal (PNH), Lymphoma, Non-Hodgkin (NHL), Myelodysplastic Syndrome (MDS)
Interventions: Miltenyi Biotec CliniMACS, Stem Cell Transplantation, TBI, systemic chemotherapy and antibodies as follows:; Device · Procedure · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 21 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Graft Vs Host Disease
Interventions: PRO 140, Placebo; Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 8
States / cities: Miami, Florida • Maywood, Illinois • Detroit, Michigan + 5 more

Conditions: Multiple Myeloma, Leukemia, Plasma Cell
Interventions: Carfilzomib, Melphalan, Filgrastim; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Blood Disease
Interventions: TCRαβ+/CD19+ depleted Hematopoietic stem cell (HSC) graft, CliniMACS® System; Biological · Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 3 Months to 25 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Acute Myeloid Leukemia and Myelodysplastic Syndrome
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Multiple Myeloma
Interventions: IV busulfan, bortezomib, Autologous Hematopoietic Stem Cell Transplant (HSCT); Drug · Procedure
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 11
States / cities: Tucson, Arizona • Atlanta, Georgia • Maywood, Illinois + 7 more

Search by objective public record fields.

Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission

Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Survivorship Post-HCT Optimization Program

Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias

Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood

Optimizing PTCy Dose and Timing

A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant

Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoietic Stem Cell Transplant Recipients

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer

Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders

Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients

A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients

Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies

A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation

Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma

Alpha/Beta T-cell Depleted Blood-forming Stem Cell Transplant From Related or Unrelated Donors for Blood Diseases in Children and Young Adults

Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant

IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients